Dare Bioscience (NASDAQ:DARE) Stock Crosses Below 200 Day Moving Average – What’s Next?

Dare Bioscience, Inc. (NASDAQ:DARE) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.97 and traded as low as $1.65. Dare Bioscience shares last traded at $1.72, with a volume of 123,858 shares trading hands.

Analyst Ratings Changes

DARE has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Dare Bioscience in a research report on Tuesday, December 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

Dare Bioscience Stock Up 3.6%

The business’s 50 day simple moving average is $1.89 and its 200 day simple moving average is $1.97. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $24.58 million, a PE ratio of -0.92 and a beta of 0.93.

Institutional Investors Weigh In On Dare Bioscience

Several large investors have recently added to or reduced their stakes in DARE. LPL Financial LLC bought a new stake in shares of Dare Bioscience in the 4th quarter valued at approximately $28,000. Raymond James Financial Inc. raised its holdings in Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 13,650 shares during the period. Virtu Financial LLC purchased a new stake in Dare Bioscience during the 3rd quarter valued at $37,000. Finally, AMH Equity Ltd lifted its position in Dare Bioscience by 20.0% in the third quarter. AMH Equity Ltd now owns 232,373 shares of the biotechnology company’s stock worth $488,000 after buying an additional 38,770 shares during the last quarter. 6.70% of the stock is owned by institutional investors.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.